Potent predictive CpG signature for temozolomide response in non-glioma-CpG island methylator phenotype glioblastomas with methylated MGMT promoter.
Epigenomics
; 14(20): 1233-1247, 2022 10.
Article
em En
| MEDLINE
| ID: mdl-36444681
Glioblastomas that do not have the glioma-CpG island methylator phenotype (G-CIMP) but have a methylated promoter of the MGMT gene (meMGMT) show considerable variability in their response to temozolomide (TMZ). Powerful biomarkers that provide predictive information on optimal TMZ decision-making can be clinically useful. This study has identified and validated a panel of 77 TMZ efficacy-related CpGs and a seven-CpG risk signature for predicting TMZ usage in non-G-CIMP meMGMT glioblastomas. An integrated classification scheme is proposed for refining a MGMT-based TMZ-guiding approach in non-G-CIMP glioblastomas.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Glioblastoma
/
Glioma
Tipo de estudo:
Prognostic_studies
/
Risk_factors_studies
Limite:
Humans
Idioma:
En
Revista:
Epigenomics
Ano de publicação:
2022
Tipo de documento:
Article